The U.S. FDA Accepted Checkpoint Therapeutics Biotech BLA for Cosibelimab

Checkpoint Therapeutics
Checkpoint Therapeutics (CKPT) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers.

Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing open-label, multi-regional, multicohort . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.